APUS Financials: Apimeds Pharmaceuticals US Inc AI Analysis



Financials

APUS Financial

Apimeds Pharmaceuticals US Inc

0%

$0

At close: Jun 26, 16:00:00 GMT-4

0%

$0

Post-market: Jun 26, 19:43:45 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is APUS?

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.

Features

Markets

News

Breakdown	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	12/31/2024
Revenue	0	0	0	0	0	0
Revenue Growth (YoY)	--	--	--	--	-100%	-100%
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	19	3	3	3	8	4
Research & Development	49	9	9	8	22	10
Operating Expenses	71	13	12	11	30	14
Other Non Operating Income (Expenses)	0	0	0	0	--	0
Pretax Income	-74	-13	-12	-11	-37	-11
Income Tax Expense	0	0	0	0	0	0
Net Income	-74	-13	-12	-11	-37	-11
Net Income Growth	--	--	9%	-31%	147%	-65%
Shares Outstanding (Diluted)	37.55	37.55	37.71	35.86	37.16	36.88
Shares Change (YoY)	--	--	2%	7%	13%	12%
EPS (Diluted)	-1.99	-0.35	-0.33	-0.33	-1	-0.3
EPS Growth	--	--	10%	-33%	117%	-68%
Free Cash Flow	-66	-14	-11	-9	-30	-13
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	--	--	--	--	--	--
Operating Margin	0%	0%	0%	0%	0%	0%
Profit Margin	0%	0%	0%	0%	0%	0%
Free Cash Flow Margin	0%	0%	0%	0%	0%	0%
EBITDA	-69	-13	-12	-11	-29	-14
EBITDA Margin	0%	0%	0%	0%	0%	0%
D&A For EBITDA	2	0	0	0	1	0
EBIT	-71	-13	-12	-11	-30	-14
EBIT Margin	0%	0%	0%	0%	0%	0%
Effective Tax Rate	0%	0%	0%	0%	0%	0%

Breakdown

TTM

03/31/2026

12/31/2025

09/30/2025

06/30/2025

12/31/2024

Revenue

Revenue Growth (YoY)

-100%

Cost of Revenue

Gross Profit

Selling, General & Admin

Research & Development

Operating Expenses

Other Non Operating Income (Expenses)

Pretax Income

-74

-13

-12

-11

-37

-11

Income Tax Expense

Net Income

-74

-13

-12

-11

-37

-11

Net Income Growth

-31%

147%

-65%

Shares Outstanding (Diluted)

37.55

37.71

35.86

37.16

36.88

Shares Change (YoY)

13%

12%

EPS (Diluted)

-1.99

-0.35

-0.33

-1

-0.3

EPS Growth

10%

-33%

117%

-68%

Free Cash Flow

-66

-14

-11

-9

-30

-13

Free Cash Flow Per Share

Gross Margin

Operating Margin

Profit Margin

Free Cash Flow Margin

EBITDA

-69

-13

-12

-11

-29

-14

EBITDA Margin

D&A For EBITDA

EBIT

-71

-13

-12

-11

-30

-14

EBIT Margin

Effective Tax Rate

Follow-Up Questions

What are Apimeds Pharmaceuticals US Inc's key financial statements?



According to the latest financial statement (Form-10K), Molecular Partners AG has a total asset of $0, Net loss of $0

What are the key financial ratios for APUS?



Molecular Partners AG's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Apimeds Pharmaceuticals US Inc's revenue broken down by segment or geography?



Molecular Partners AG largest revenue segment is Biopharmaceutical Products, at a revenue of 7,038,000 in the most earnings release.For geography, Switzerland is the primary market for Molecular Partners AG, at a revenue of 7,038,000.

Is Apimeds Pharmaceuticals US Inc profitable?



no, according to the latest financial statements, Molecular Partners AG has a net loss of $0

Does Apimeds Pharmaceuticals US Inc have any liabilities?



no, Molecular Partners AG has liability of 0

How many outstanding shares for Apimeds Pharmaceuticals US Inc?



Molecular Partners AG has a total outstanding shares of 0

Apimeds Pharmaceuticals US Inc (APUS) Financial

APUS Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is APUS?

Apimeds Pharmaceuticals US Inc (APUS) Financial

APUS Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is APUS?

APUS Income

Follow-Up Questions

What are Apimeds Pharmaceuticals US Inc's key financial statements?

What are the key financial ratios for APUS?

How is Apimeds Pharmaceuticals US Inc's revenue broken down by segment or geography?

Is Apimeds Pharmaceuticals US Inc profitable?

Does Apimeds Pharmaceuticals US Inc have any liabilities?

How many outstanding shares for Apimeds Pharmaceuticals US Inc?